Türk Kardiyoloji Derneği Ulusal Hipertansiyon Tedavi ve Takip Kılavuzu

KAYNAKLAR

1. Taguchi JF, Freis ED: Partial reduction of blood pressure and prevention of complications in hypertension. N Engl J Med 1974; 291: 329-31.

2. Isles CG, Walker LM, Beevers GD et al: Mortality in patients in the Glascow Blood Pressure Clinic. J Hypertens 1986; 4: 141-56.

3. Burt VL, Whelton P, Rocello EJ, et al: Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25: 305-13.

4. Collins R, Peto R, MacMahon S, et al: Blood pressure, stroke and coronary heart disease. Part 2, Short term reduction in blood pressure overwiev of randomised drug trials in their epidemyological context. Lancet 1990; 335: 827-39.

5. Collins R, MacMahon S: Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50: 272-98.

6. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997; 157: 2413-46

7. Guidelines Subcommittee of the World Health Organization: World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17:151-83

8. Ramsay LE, Wallis EJ, Yeo WW, Jackson PR: The Rational for differing national recommendations for the treatment of hypertension. Am J Hypertens 1998; 11: Part 2, 79S-88S.

9. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL: The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557-62.

10. Moser M, Hebert PR: Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996; 27: 1214-8.

11. Colhoun HM, Dong W, Poulter NR: Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens 1998; 16: 747-52.

12. Moser M: Clinical Management of Hypertension. Professional Communications Inc. Second edition 1997, pp. 13-7.

13. Guyatt GH, Sackett DL, Sinclair JC, Hayward R, Cook DJ, Cook RJ for the Evidence-based Medicine Working Group: Users’ guides to the medical literature. IX. A method for grading Health Care Recommendations. JAMA 1995; 274: 1800-4.

14. Fahey T, Griffiths S, Peters TJ: Evidence based purchashing: understanding results of clinical trials and systematic reviews. BMJ 1995; 311: 1056-9.

15. Hypertension Detection and Follow-up Program Cooperative Group: Five-year findings of the HDFP: I. Reduction in mortality of persons with high blood pressure including mild hypertension. JAMA 1979; 242: 2562-72.

16. Tyroler HA: Socioeconomic status in the epidemiology and treatment of hypertension. Hypertension 1989; 13(SupplI): 194-7.

17. Jönsson B: Measurement of health outcome and associated costs in cardiovascular disease. Eu Heart J 1996; 17: 2-7

18. Ambrosioni E, Costa FV: Cost-effectiveness calculations from trials. J Hypertens 1996; 14(Suppl2): S47-S54

19. Chalmers J, Zanchetti A: Reply to a critique of the

1996 World Health Organization expert commitee report on hypertension. J Hypertens 1997; 15: 684-5.

20. Mancia G, Sega R, Milesi C, Cesana G, Zanchetti A: Blood pressure control in the hypertensive population. Lancet 1997: 349; 454-7

21. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Menard J et al: For the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-62.

22. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP) JAMA 1991; 265: 3255-64.

23. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al: for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-64.

24. Medical Research Council Working Party. MRC trial of mild hypertension: principal results. Br Med J 1985; 291: 197-204

25. Flack J, Neaton J, Grimm R, Shih J, Cutler J, Ensrud K, et al: for the Multiple Risk Factor Intervention Trial Research Group. Blood pressure and mortality among men with prior myocardial infarction. Circulation 1995; 92: 2437-45.

26. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults principal results. BMJ 1992; 304: 405-12.

27. Hypertension Detection and Follow-up Program Cooperetive Group: The effect of treatment on mortality in’’mild’’ hypertension: results of the Hypertension Detection and Follow-up Program. N Engl J Med 1982; 307: 976-80.

28. Kaplan N: Measurement of blood pressure. Clinical Hypertension. Williams and Wilkins, USA 7th ed. 1998, p. 19-39 ve 181-248

29. Haynes RB, Lacourcière Y, Rabkin SW: Report of the Canadian Hypertension Society Consensus Conference: Diagnosis of hypertension in adults. Canadian Medical Association Journal 1993; 149: 409-18

30. Mancia G, Sega R, Bravi C et al: Ambulatory blood pressure normality: results from the PAMELA study. J Hypertens 1995; 12: 1377-90

31. National High Blood Pressure Education Program (NHBPEP) Working Group Report on Ambulatory Blood Pressure Monitoring. National Institutes of Health National Heart, Lung, And Blood Institute NIH Publication No. 92-3028 reprinted February 1992

32. Graettinger W, Lipson J, Cheung D, Weber M: Validation of portable noninvasive blood pressure monitoring devices: Comparisons with intra-arterial and sphygmomanometer measurements. Am Heart J 1988; 116: 1155-60

33. Zanchetti A: The role of ambulatory blood pressure monitoring in clinical practice. Am J Hypertens 1997; 10: 1069-80

34. Fagard R, Brauljan J, Thijs L, Staessen J: Prediction of the actual awake and asleep blood pressures by various methods of 24h pressure analysis. J Hypertens 1996; 14: 557-563

35. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G: Relationship of 24-hour blood pressure mean and variability to severity of target organ damage in hypertension. J Hypertens 1987; 5: 93-8

36. Perloff D, Sokolow M, Cowan R: The prognostic value of ambulatory blood pressures. JAMA 1983; 249: 2792-8

37. White WB, Dey HM, Schulman P: Assessment of the daily blood pressure load as a determinant of cardiac function in patients with mild to moderate hypertension. Am Heart J 1989; 118: 782-95

38. Pickering TG: Blood pressure monitoring outside the office for the evaluation of patients with resistant hypertension. Hypertension 1988; 11: II96-II100

39. Omboni S, Parati G, Zanchetti A, Mancia G: Calculation of trough: peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects. J Hypertens 1995; 13: 1105-12

40. Cooper RS: Geographic patterns of hypertension: a global perspective. Izzo JL, Black HR(eds ): Hypertension Primer: The essentials of high blood pressure (2 nd ed). Am Heart Assn, Dallas TX, 1999 p 224-5

41. Onat A, Şenocak M, Örnek E ve ark: Türk Erişkinlerinde Kalp Hastalığı ve Risk Faktörleri Taraması: 5. Hipertansiyon ve sigara içimi. Türk Kardiyoloji Derneği Arş. 1991; 19: 169-77

42. Onat A, Dursunoğlu D, Sansoy V ve ark: Türk erişkinlerinde kan basıncında yeni eğilimler: TEKHARF çalışması 1990 ve 1995 verilerinin analizi. Türk Kardiyoloji Derneği Arş 1996; 24: 73-81

43. Onat A, Sansoy V, Yıldırım B ve ark: Erişkinlerimizde kan basıncı: 8-yıllık seyri, tedavi oranı, koroner kalp hastalığı ile bazı etkenlerle ilişkileri. Türk Kardiyoloji Derneği Arş 1999; 27: 136-43

44. Mulrow PJ: Hypertension-a worldwide epidemic. Izzo JL, Black HR (eds): Hypertension Primer: The essentials of high blood pressure (2 nd ed). Am Heart Assn, Dallas TX, 1999 p 271-73

45. Calhoun DA, Oparil S: Gender and blood pressure. Izzo JL, Black HR (eds): Hypertension Primer: The essentials of high blood pressure (2 nd ed). Am Heart Assn, Dallas TX, 1999p 229-32

46. Onat A, Dursunoğlu D, Sansoy V: Relatively high coronary death and event rates in Turkish women: Relation to three major risk factors in five-year follow-up of cohort. Int J Cardiol 1997; 61: 69-77

47. Onat A, Sansoy V: Systolic and diastolic blood pressure related to six other risk parameters in Turkish adults: Strong correlation with relative weight. Int J Cardiol, 1998; 63: 295-303

48. Pickering G: Hypertension. Definitions, natural histories and consequences. Am J Med 1972; 52: 570-83.

49. Parati G, Ulian L, Santucciu C, Omboni S, Mancia G: Difference between clinic and day time blood pressure is not a measure of the white coat effect. Hypertension 1998: 31; 1185-9

50. Nalbantgil İ, Kılıçcıoğlu B, Önder R, Boydak B, Terzioğlu E, İşler M: “Beyaz Gömlek” hipertansiyonuna yaş ve cinsiyetin etkisi. Türk Kardiyol Dern Arş 1993: 21; 182-3

51. Nalbantgil İ, Kılıçcıoğlu B, Önder R, Yılmaz H, Terzioğlu E: Ambulatory blood pressure monitoring must be employed for twenty-seven hours instead of twenty-four hours. J Ambulat Monit 1994: 7; 247-52

52. Nalbantgil İ, Önder R, Nalbantgil S, Yılmaz H, Boydak B: The prevalance of silent myocardial ischemia in patients with white-coat hypertension. J Human Hypertens 1998: 12; 337-41

53. Rudnick JV, Sackett DL, Hirst S, and Holmes C: Hypertension in family practice. Can Med Assoc J 1977; 3: 492.

54. Sinclair AM, Isles CG, Brown I et al: Secondary hypertension in blood pressure clinic. Arch Intern Med 1987; 147: 1289.

55. Cutler JA, StamlerJ: Prevention of hypertension. İzzo JL, Black HR (eds): Hypertension Primer: The essentials of high blood presssure (2th ed). Am Heart Assn, Dallas TX, 1999 p. 274-8.

56. Stamler J, Caggiula A, Grandits GA, Kjelsberg M: Cutler JA for the MRFIT research group: Relationship to blood pressure of combinations of dietary macronutrients: findings of the multiple risk factor intervention trial (MRFIT). Circulation 1996; 94: 2417-23.

57. Stamler R, Stamler J, Gorch FC et al: Primary prevention of hypertension by nutritional-hygienic means: final report of a randomized, controlled trial. JAMA 1989; 262: 1801-7.

58. Hypertension Prevention Trial Research Group: The Hypertension Prevention Trial: three-year effects of dietary changes on blood pressure. Arch Intern Med 1990; 150: 153-62.

59. The Trials of Hypertension Prevention Collaborative Research Group: The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels: results of the Trials of Hypertension Prevention, phase I. JAMA 1992; 1213-20.

60. The Trials of Hypertension Prevention Collaborative Research Group: Effects of weight loss and sodium

reduction intervention on blood presure and hypertension incidence in overweight people with high-normal blood pressure: the trials of Hypertension Prevention, phase II. Arch Intern Med 1997; 157: 657-67.

61. Irie K, Yamaguchi T, Minematsu K, Omae T: The J-curve phenomenon in stroke recurrence. Stroke 1993: 24; 1844 -9

62. National Institutes of Health: Working Group report on primary prevention of hypertension. NIH Pub. no: 93-2669, 1993

63. Swales JD: Manual of Hypertension. Blackwell Science Ltd. London, 1995; pp 153-60.

64. Cutler JA, Follman D, Allender PS: Randomized trials of sodium reduction: an overview. Am J Clin Nutr 1997; 65 (Suppl): 643-51.

65. Khan MG: Hypertension in Heart Disease Diagnosis and Therapy. A Practical approach. Khan MG, Topol EJ, Saksena S, Goodwin JF. (eds.). Williams and Wilkins Comp. Baltimore, 1996 p. 323-78

66. Oates JP: Antihypertensive agents and the drug therapy of hypertension In: Goodman Gilmans the Pharmacological Basis of Therapeutics. Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A. (eds. ) Ninth Ed. Mc Graw Hill Comp. New York, 1996 p. 780-808

67. Nayler WG: The Pharmacology of the Calcium Antagonists in Hypertension the Next Decade. Fleckenstein A, Laragh JH. (eds). Churchill Livingstone, London, 1987, p. 53-66

68. Ehring T, Heusch G: Dihydropyridine calcium antagonists. Benefical or adverse effects in the setting of myocardial ischaemia/reperfusion. Cardiology, 1997; 88 (Suppl. I): 3-14

69. Laurence DR, Bennett PN: Kidney and urinary tract. Diuretics. in Clinical Pharmacology. Laurence DR, Bennett PN. (eds. ) Seventh Ed. ELBs with Churchill Livingstone Edinburgh, 1992, p. 459-47

70. Sobel BJ, Bakris GL: Treatment of the hypertensive patient in hypertension. A Clinicians Guide to diagnosis and Treatment. Sobel BJ, Bakris GL. (Eds. ) Hanley and Belfur Inc. /Philadelphia, 1995, p. 29-46

71. Schols H: Pharmacological aspects of calcium channel blockers. Cardiovasc Drugs Ther 1997; 10: 869-72

72. Psaty BM, Smith NL, Siscovick DS, et al: Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA 1997; 277: 739-45

73. Wyngaarden JB, Smith LH: Cecil Textbook of Medicine, Eighteened edition. Philadelphia: W B Saunders Company 1988; 286-8

74. Özcan R (ed) et al: Kalp Hastalıkları. İstanbul, Sanal Matbaası 1983; 596-7

75. Moser MA: Critique of the World Health Organization: International Society of Hypertension Guidelines for the Management of Hypertension. Cardiovascular Reviews & Reports 1999; 20: 4: 1-4

76. Farnett L, Mulrow CD, Linn WD et al: The J-curve phenomenon and the treatment of hypertension: is there a point beyond which pressure reduction is dangerous?JAMA 1991; 265: 489-95

77. Weber MA: Cardiology Clinics. Philadelphia, W B Saunders Company 1995; 13: 4: 509-27

78. WHO Expert Committee. Hypertension Control. WHO Technical Report Series 862, Geneva, 1996

79. Nalbantgil İ, Nalbantgil S: Antihipertansif tedavide kombinasyon tedavisi. Galenos 1998: 2; 40-4

80. Mancia G, Grassi G. Antihypertensive treatments: past, present and future. J Hypertens 1998: 16 (suppl 1); S1- S7

81. Messerli FH: Cardiovascular Drug Therapy. New Orleans. W. B. Saunders Comp. Second Edit. 1996

82. American Heart Association: Hypertension Primer. Second Edit. Williams&Wilkins. Dallas, Texas. 1999: 358-89

83. Sibai BM: Treatment of hypertension in pregnant women. N Engl J Med 1996; 335: 257-65

84. Kaplan N: Clinical Hypertension. Baltimore. Williams& Wilkins 1994 p: 343

85. Dahlöf B, Lindholm LH, Hansson L. et al: Morbidity and mortality in the Swedish Trial in old patients with hypertension (STOP hypertensıon). Lancet 1991, 338: 128l-5

86. Messerli FH, Sundgaard R K, Ventura et al: Essential hypertensıon in the elderly; haemodynamıcs, intravascular volume, plasma renin actıvity and circulating catecholamine levels. Lancet l983, ii 983-6

87. Safar ME, Cloarec-Blanchard L, London GM: Arterial alterations in hypertensıon with disproportionate increase in systolıc over diastolic blood pressure. J Hypertens l996; l4 (suppl 2): S l03-l0

88. Darne B, Girard X, Safer M et al: Pulsatile versus steady component blood pressure: a cross sectıonal analysıs and a prospective on cardiovascular mortality. Hypertensıon 1989; 13: 392-400

89. Safar ME: Haemodynamic changes in elderly hypertensive patients. Am J Hypertens l993; 6: 20S-3S

90. Saltzberg S, Stroh JA, Frishman WH: Isolated systolic hypertension in the elderly: Pathophysiology and Treatment. Med Clin North Am l988; 72: 523-47

91. Beard K, Bulpitt C, Masscie-Taylor H et al: Management of elderly patients with sustained hypertension BMJ l992; 304: 4l2-6

92. Black HR: Age related issues in the treatment of hypertension. Am J Cardıol l993; 72: H l0-3

93. Fiebach NH, Herbert PR, Stumpfer MJ et al: A prospectıve study of high blood pressure and cardiovasculer disease in women. Am J Epidemiol 1989; 130: 646-54

94. Hypertension Detection and Follow-up Program Cooperatif Group. Five-year findings of the hypertension detection and follow-up program. II. Mortality by race, sex and age. JAMA 1979; 242: 2572-7

95. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen-Progestin intervention (PEPI) Trial. JAMA 1995; 273: 199-208

96. National High Blood Pressure Education Program Working Group Report on Hypertension Control in Children and Adolescents. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: A working group report from the National High Blood Pressure Education Program. Pediatrics. 1996; 98: 649-58

97. Lieberman E: Hypertension in childhood and adolescence. Kaplan (ed) Clinical Hypertension 5th ed. Baltimore, Williams and Wilkins, 1990

98. Jung FF, Ingelfinger JR: Hypentension in childhood and children. Ped Rewv1993, 14: 169

99. Hiner L, Felkner B: Essential Hypertension in Childhood and Adolescence. Child Nephrol Urol 1992; 12: 119-23

100. Loggie JMH: Evaluation and management of childhood hypentension. Surg Clin North Am Pediatr Surg

1985; 2: 1623-49

101. Kaplan RA, Hellerstein S, Alon U: Evaluation of the hypertensive child. Child Nephrol Urol 1992; 12: 106-112

102. Rocchini AP: Adolescent obesity and hypertension Pediatr Clin North Am 1993; 40: 811-92

103. Sinaiko AR: Hypertension in Children. N Engl J

Med 1996; 335: 1968-73

104. Sinaiko AR: Pharmacologic management of childhood hypertension. Pediatr Clin North Am 1993; 40: 195-212

105. Sinaiko AR, Donahue RP, Jacobs DR et al: Relation of weight and rate of increase in weight durung childhood and adolescence to body size, blood pressure, fasting insulin and lipids in young adults. The Minneapolis

Children’s Blood Pressure Study. Circulation, 1999; 99: 1471-6

106. Haffner SM: Syndrome X: Insulin resistance-hyperinsulinemia the key. M. Hanefeld and W. Leonhardt (eds). The Metabolic Syndrome. Stuttgart Gustav Fisher Verlag 1997 p: 25

107. American Diabetes Association. American Diabetes Association: clinical practice recommendation. Diabetes Care 1997; 20(suppl): S1-S70

108. Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin converting enzyme in non-insulin dependent diabetes mellitus: a 7- year follow-up study. Arch intern Med 1996; 156: 286-9

109. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney int 1996; 50: 1641-50

110. MacMahon S, Peto R, Cutler J ve ark: Blood pressure, stroke and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74

111. Multiple Risk Factor Intervention Trial Group. Multiple Risk Factor Intervention Trial: Risk factor changes and mortality results. JAMA 1982; 248: 1465-77

112. Levy D, Wilson P W, Anderson K ve ark: Stratifying the patient at risk from coronary disease: New insights from the Framingham study. Am Heart J 1990; 119: 712-7

113. Kannel W B, Sorlie P, Castelli W P ve ark: Blood pressure and survival after myocardial infarction: The Framingham study. Am J Cardiol 1980; 45: 326-30

114. Yusuf S: Calcium antagonists in coronary artery disease and hypertension-time for reevaluation ? Circulation 1995; 92: 1079-82

115. Lorell BH: Transition from hypertrophy to failure. Circulation 1997, 96: 3824 -7

116. Al-Khadra, A: Hypertensive left ventricular hypertrophy: A review. J Saudi Heart Ass 1998,10:132- 8

117. European Study Group on Diastolic Heart Failure: How to diagnose diastolic heart failure. Eur Heart J 1998, 19: 990 - 1003

118. Park SH, Shub C, Nobrega TP et al: Two - dimensional echocardiographic calculation of left ventricular mass as recommended by the American Society of Echocardiography: correlation with autopsy and M-mode echocardiography. J Am Soc. Echocardiography 1996, 9: 119 - 28

119. Assayag P, Carré F, Chevalier B, et al: Compensated cardiac hypertrophy: arrhythmogenicity and the new myocardial phenotype. I. Fibrosis. Cardiovasc Res 1997, 34: 439 -44

120. Swynghedauw B, Chevalier B, Charlemange D, et al: Cardiac hypertrophy, arrhythmogenicity and the new myocardial phenotype. II. The cellular adaptational process. Cardiovasc Res 1997, 35: 6 -12

121. Brooks WW, Bing OHL, Robinson KG, et al: Effect of angiotensin converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing

myocardium from the spontaneously hypertensive rat. Circulation 1997, 96: 4002 -10

122. Olivetti G, Capasso JM, Sonnenblick EH, Ricci R, Puntillo E, Anversa P: Differences in the temporal effects of aging on the structure and the function of rat myocardium. Coron Artery Dis 1990; 1: 240-50

123. Olivetti G, Melissari M, Caposso JM, Anversa P: Cardiomyopathy of the aging human heart myocyte loss and reactive cellular hypertrophy. Circ Res 1991; 68: 1560-8.

124. Snyder SO, Molnar RG: Diagnosing abdominal aortic aneurism: An update. Hospital Medicine 1998; 34: 47-8

125. Santilli JD, Santilli SM: Diagnosis and treatment of abdominal aortic aneurisms. American Family Physician 1997; 56: 1081-90

126. Braunwald E: Heart Disease. A Textbook of Cardiovascular Disease. WB Saunders Company, 5th edition, Philadelphia, 1997

127. Amstrong WF, Bach DS, Carey LM, Froelich J, Lowell M, Kazerooni E: Clinical and echocardiographic findings in patients with suspected acute aortic dissection. Am Heart J 1998; 136(6): 1051-60

128. Torossov M, Singh A, Fein SA: Clinical presentation, diagnosis, and hospital outcome of patients with documented aortic dissection: The Albany Medical Center Experience, 1986 to 1996. Am Heart J 1999, 137: 154-61

129. Hughsen WG, Mann JI, Garrod A: Intermittent claudication; prevalence and risk factors. BMJ 1978; 1: 379-81

130. Dawber TR: The Framingham Study. The epidemiology of atherosclerotic disease. Cambridge, Ma: Harvard University Press, 1980

131. Wagener HP, Clay GE, Gipner JF: Clasification of retinal lesions in the presence of vascular hypertension. Trans Am Ophtalmol Soc 1947; 43: 57-73

132. Gangevoort RT, Navis GJ, Wapstra FH, et al: Proteinuria and progression of renal disease: Therapeutic imp-

lications. Curr Opin Nephrol Hypertens 1997; 6: 133-140

133. Brown MA, Whithworth JA: Hypertension in human renal disease. J Hypertens 1992; 10: 701-12

134. Buckalew VM, Berg RL, Wang SR, et al: Prevalence of hypertension in 1795 subjects with chronic renal disease: The modification of diet in renal disease study baseline cohort. Am J Kidney Dis 1996; 28: 811-21

135. Locatelli F, Marcelli D, Comelli M, et al: Proteinuria and blood pressure as causal components of progression to end stage renal disease. Nephrol Dial Transplant 1996; 11: 461-7

136. Maki DD, Ma JZ, Louis TA, et al: Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995; 155: 1073-80

137. Klag MJ, Whelton PK, Randall BI, et al: Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13-8

138. Pickering TG, Mann SJ: Renovascular hypertension: Medical evaluation and non-surgical treatment. In Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis and Management. New York, Raven Press, 1995.

139. National High Blood Pressure Education Program: National High Blood Pressure Education Program Working Group on Hypertension and Chronic Renal Failure. Arc Intern Med 1991; 151: 1280-7

140. Working Group on Renovascular Hypertension. Detection, Evaluation, and Treatment of Renovascular Hypertension. Arc Intern Med 1987; 147: 820-9

141. Akçiçek F (ed): Sürekli Ayaktan Periton Diyalizi (SAPD) Temel Bilgiler Kitabı. Türk Nefroloji Derneği Yayınları, Bornova, İzmir, 1997.

142. Mees DEJ, Özbaşlı Ç, Akçiçek F: Cardiovascular disturbances in hemodialysis patients. J Nephrol 1995; 8: 71-8

143. Curtis JJ: Hypertension following kidney tranplantation. Am J Kidney Dis 1994; 23: 471-5

144. Curtis JJ, Luke R, Jones P, et al: Hypertension in cyclosporine-treated renal transplant patients is sodium dependent. Am J Med 1988; 85: 134 -8

145. Curtis JJ, Luke RG, Diethelm AG, et al: Benefits of removal of native kidneys in hypertension after renal transplantation. Lancet 1985; II: 739-42

146. Kumral E, Özkaya B, Sağduyu A ve ark: The Ege Stroke Registry: a hospital-based study in the Aegean region, İzmir, Turkey. Cerebrovasc Dis 1998; 8: 278-88

147. Sacco RL, Benjamin EJ, Broderick JP ve ark: Risk factors. Stroke 1997: 28: 1507-17

148. Davis BR, Vogt T, Frost PH ve ark: Risk factor for stroke and type of stroke in persons with isolated systolic hypertension. Stroke 1998: 1333-40

149. Bogousslavsky J, Castillo V, Kumral E, Henriques I, Melle GV: Stroke subtypes and hypertension. Primary hemorrhage vs infarction, large vs small-artery disease. Arch Neurol 1996: 53: 265-9

150. Kumral K, Kumral E. Hipertensif ansefalopati: I. Santral sinir sisteminin damarsal hastalıkları. Ege Üniversitesi Basımevi, 1993: 433-6

151. Domino KB: Perioperative Hypertension. 46th Annual Refresher Course Lectures and Clinical Update Program. American Society of Anesthesiologists. USA. 1995, P: 115; 1-7

152. Prys-Roberts C, Meloche R, Foex B: Studies of anesthesia in relation to hypertension I: Cardiovascular responses of treated and untreated patients. Br J Anesth. 43: 122, 1971

153. Edde RR: Hemodynamic changes prior to and after sternotomy in patients anesthetized with high-dose fentanyl. Anesthesiology 55: 444, 1981

154. Wynands JE, Towsend GE, Wong P, et al: Blood Pressure and Plasma Fentanyl Concentrations During High and Very-High Dose Fentanyl Anesthesia for Coronary Artery Surgery. Anest. Analg. 62: 661, 1983

155. Morgan E, Mikhail MS: Clinical Anesthesiology. 2nd, Ed. , Appleton & Lange, USA, 1996, p. 341-76

156. Goldman L, Caldera DL: Risk of general anesthesia and elective operation in hypertensive patient. Anesthesiology. 50: 285-292, 1979

157. Stoelting RK, Dierdorf SF: Anesthesia and CO-existing Disease. 3rd. Ed. , Churchill Livingstone, New York, 1993, p. 79-86

158. Miller ED: Anesthesia and hypertensive patient. International Anesthesia Research Society 1987 Course Lectures, USA, 1987, p. 6-10

159. Abdelwahop W, Frishman W, Landau A: Management of hypertensive urgencies and emergencies. J Clin Pharmacol 1995; 35: 747-62

160. Kaplan NM: Management of hypertensive emergencies. Lancet 1994; 344: 1335-8

161. Hirschl MM: Guidelines for the drug treatment of hypertensive crises. Drugs 1995; 50: 991-1000.